Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN65,1165,142,13
Msft-0,17
Nokia3,29053,2965-1,02
IBM0,08
Mercedes-Benz Group AG73,8573,870,39
PFE-0,11
29.03.2024 1:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 28.03.2024
GlycoMimetics (NASDAQ Cons)
Závěr k 28.3.2024 Změna (%) Změna (USD) Objem obchodů (ks)
3,00 -5,66 -0,18 652 824
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 29.03.2024
Popis společnosti
Obecné informace
Název společnostiGlycoMimetics Inc
TickerGLYC
Kmenové akcie:Ordinary Shares
RICGLYC.O
ISIN-
Prioritní akciePreference Shares
Poslední známé roční výsledky31.12.2022
Poslední známé čtvrtletní výsledky30.09.2023
Počet zaměstnanců k 31.12.2022 38
Akcie v oběhu k 01.11.2023 64 393 294
MěnaUSD
Kontaktní informace
Ulice9708 Medical Center Drive
MěstoROCKVILLE
PSČ20850
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon12 402 431 201
Fax12402431018

Business Summary: GlycoMimetics, Inc. is a clinical-stage biotechnology company, which is focused on the discovery and development of glycomimetic drugs. It is developing a pipeline of glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in biological processes, to inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer, and infection. Its drug candidates include Uproleselan, GMI-1359, GMI-1687, and Galectin Antagonists. It is developing Uproleselan, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia (AML). Its GMI-1359 targets both E-selectin and a chemokine receptor known as CXCR4. It has designed an antagonist of E-selectin, GMI-1687, that is suitable for subcutaneous administration. The Company is engaged in advancing other preclinical-stage programs, including small-molecule glycomimetic compounds that inhibit the protein galectin-3.
Financial Summary: BRIEF: For the nine months ended 30 September 2023, GlycoMimetics Inc revenues decreased from $75K to $0K. Net loss decreased 24% to $27.8M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects researcg and development expense balanc decrease of 62% to $8.3M (expense), General & Administrative Expe decrease of 38% to $7.6M (expense).
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Bio Therapeutic Drugs
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
NAICSPharmaceutical Preparation Manufacturing
NAICS2007Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
NAICS2007Pharmaceutical Preparation Mfg
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
NAICS1997Pharmaceutical Preparation Manufacturing
SICPharmaceutical Preparations
SICCommercial Physical Research
SICPharmaceutical Preparations



  • Poslední aktualizace: 29.03.2024
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, DirectorHarout Semerjian5206.08.202106.08.2021
Co-Founder, DirectorRachel King6306.08.202101.01.2003
Chief Financial Officer, Senior Vice President - FinanceBrian Hahn48
Senior Vice President, Chief Commercial OfficerBruce Johnson5523.02.202223.02.2022
Senior Vice President, Chief Business OfficerChinmaya Rath47
Senior Vice President, Chief Medical OfficerEdwin Rock6206.09.202206.09.2022